International Clinical Trial: A Phase II Clinical Trial of PD-L1 Expression-Based Epaploitovorilimab Combined with Chemotherapy as First-Line Treatment for Metastatic Gastric Cancer: Single-Arm, Open-Label

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115675) titled 'A Phase II Clinical Trial of PD-L1 Expression-Based Epaploitovorilimab Combined with Chemotherapy as First-Line Treatment for Metastatic Gastric Cancer: Single-Arm, Open-Label' on Dec. 30, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Bengbu Medical University

Condition: Gastric Cancer

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2025-12-30

Target Sample Size: Research group:30;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=303117

Disclaimer: Curated by HT S...